Skip to main content
OpenTrials
Completed

NCT Number: NCT04343339

Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment

The current containment linked to COVID-19 will have consequences for people suffering from addiction and there is a risk of overdoses when the containment ends. So the investigators hypothesize that this health crisis is an opportunity to develop risk reduction and access to care for vulnerable people who lives with an addiction.

The main objective of this study is to describe the changes in the psychoactive substances consumption during the containment in people suffering from addiction. The secondary objectives are to describe the evolution at 1 month from the end of the containment of problematic consumption and the level of access to care of these users

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Addiction, Substance COVID-19 Chemically-Induced Disorders Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Mental Disorders Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Substance-Related Disorders Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Uhmontpellier

Montpellier, 34295, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • >18 years
  • Accept study
  • live with an addiction

Exclusion criteria

  • not being able to answer the questionnaire

Treatment and study plan

Primary outcomes

  1. Evolution of consumption

    Time frame: 1 day

    measurement of the difference in drugs consumption caused by containment (delta)

  2. Evolution of consumption

    Time frame: 1 month after confinmant

    measurement of the difference in drugs consumption caused by containment (delta)

Secondary outcomes

  1. health care access

    Time frame: 1 day

    number of drug users referred to care (%)

  2. health care access

    Time frame: 1 month after confinmant

    number of drug users referred to care (%)

Sponsors and collaborators

Lead sponsor

University Hospital, Montpellier

Other

Registry information

Official study title

Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment - EPILOGUE

Acronym: EPILOGUE

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Apr 13, 2020
Registry last updated
Oct 8, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.